The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study

BACKGROUND: This phase Ib trial assessed safety, tolerability, and maximum tolerated dose (MTD) of figitumumab (CP-751,871), a fully human monoclonal antibody targeting the insulin-like growth factor type 1 receptor (IGF-IR), in combination with docetaxel. METHODS: Patients with advanced solid tumou...

Descripción completa

Detalles Bibliográficos
Autores principales: Molife, L R, Fong, P C, Paccagnella, L, Reid, A H M, Shaw, H M, Vidal, L, Arkenau, H-T, Karavasilis, V, Yap, T A, Olmos, D, Spicer, J, Postel-Vinay, S, Yin, D, Lipton, A, Demers, L, Leitzel, K, Gualberto, A, de Bono, J S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2920021/
https://www.ncbi.nlm.nih.gov/pubmed/20628389
http://dx.doi.org/10.1038/sj.bjc.6605767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2920021/
https://www.ncbi.nlm.nih.gov/pubmed/20628389
http://dx.doi.org/10.1038/sj.bjc.6605767

Ejemplares similares